Masoud Azodi - Concepedia

Author

Masoud Azodi

Yale University ORCID

Also Known As

Gustavo Rodriguez, M AZODI, M Azodi, M. AZODI, M. Azodi, Masoud Azodi, Mazu Azodi, Nayfield, Susan G.

422

Publications

7.9K

Citations

H-Index

Concepts

All Affiliations

Yale University University of Brescia University of Arkansas for Medical Sciences Università Campus Bio-Medico Yale New Haven Hospital

About

Masoud Azodi is an author at Yale University specializing in medicine, oncology, and obstetrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	53	2.6K
2	Engineering	3	3	85
3	Public Health	3	3	95
4	Health Sciences	2	2	71
5	Nursing	1	1	23

Masoud Azodi

119

Publications

7.2K

Citations

H-Index

Page 1

	Year	Citations
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial Kathleen N. Moore, Angeles Alvarez Secord, Melissa A. Geller, The Lancet Oncology OncologyMetronomic TherapyGynecologyNiraparib MonotherapyLate-line Treatment	2019	516
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu Amanda N. Fader, Dana M. Roque, Eric R. Siegel, Journal of Clinical Oncology	2018	509
Association of Type and Location of<i>BRCA1</i>and<i>BRCA2</i>Mutations With Risk of Breast and Ovarian Cancer Timothy R. Rebbeck, Nandita Mitra, Fei Wan, JAMA	2015	484
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma Siming Zhao, Murim Choi, John D. Overton, Proceedings of the National Academy of Sciences	2013	333
Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis Amanda N. Fader, Dana M. Roque, Eric R. Siegel, Clinical Cancer Research	2020	292
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition Siming Zhao, Stefania Bellone, Salvatore Lopez, Proceedings of the National Academy of Sciences	2016	227
Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy Michael Kelly, David M. O’Malley, Pei Hui, Gynecologic Oncology Surgical OncologyGynecological SurgerySurgical StageMedicineGynecology	2005	200
Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease☆ Jinlin Hou, Martina Kelly, Hon J. Yu, Gynecologic Oncology Surgical OncologyGynecological SurgeryNeoadjuvant ChemotherapyAdvanced Ovarian CancerMedicine	2007	176
Adenocarcinoma in Situ of the Cervix: Management and Outcome Masoud Azodi, Setsuko K. Chambers, Thomas Rutherford, Gynecologic Oncology	1999	117
Integrated mutational landscape analysis of uterine leiomyosarcomas Jungmin Choi, Aránzazu Manzano, Weilai Dong, Proceedings of the National Academy of Sciences	2021	113

Page 1